A Phase 1 trial of pf-03084014 in patients with advanced solid tumor malignancy and t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma - ND
Phase 1
- Conditions
- advanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).MedDRA version: 9.1Level: LLTClassification code 10066110MedDRA version: 9.1Level: LLTClassification code 10065252MedDRA version: 9.1Level: LLTClassification code 10065923
- Registration Number
- EUCTR2010-022036-36-IT
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients with acute T-ALL/LBL that are refractory/resistant to current treatment options or for which no standard therapy is available.
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Prior treatment with a gamma secretase inhibitor or an anti-Notch receptor antibody for treatment of cancer
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method